BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

April 26, 2017
Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors originally developed as cancer treatments to create a drug that can tackle all known and likely future strains of the influenza virus.
Previous Video
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture...

Next Video
Testimonials highlight opportunities for China cross-border collaboration
Testimonials highlight opportunities for China cross-border collaboration

ChinaBio® Partnering Forum 2017 meets May 31–June 1 in Zhuhai, China. Don’t miss the abundant opportunities...